+ |
nintedanib | down-regulates activity
chemical inhibition
|
KDR |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-257802 |
|
|
in vitro |
|
pmid |
sentence |
18559524 |
In this report, we describe the preclinical profile of BIBF 1120, a combined VEGFR, FGFR, and PDGFR inhibitor currently entering phase III clinical studies in non–small cell lung carcinoma and other cancers. |
|
Publications: |
1 |
Organism: |
In Vitro |
+ |
nintedanib | down-regulates
chemical inhibition
|
KDR |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-190305 |
|
|
Homo sapiens |
|
pmid |
sentence |
Other |
|
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
nintedanib | down-regulates activity
chemical inhibition
|
PDGFRB |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-257799 |
|
|
in vitro |
|
pmid |
sentence |
18559524 |
In this report, we describe the preclinical profile of BIBF 1120, a combined VEGFR, FGFR, and PDGFR inhibitor currently entering phase III clinical studies in non–small cell lung carcinoma and other cancers. |
|
Publications: |
1 |
Organism: |
In Vitro |
+ |
nintedanib | down-regulates activity
chemical inhibition
|
FGFR4 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-257803 |
|
|
in vitro |
|
pmid |
sentence |
18559524 |
In this report, we describe the preclinical profile of BIBF 1120, a combined VEGFR, FGFR, and PDGFR inhibitor currently entering phase III clinical studies in non–small cell lung carcinoma and other cancers. |
|
Publications: |
1 |
Organism: |
In Vitro |
+ |
nintedanib | down-regulates activity
chemical inhibition
|
FGFR1 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-257804 |
|
|
in vitro |
|
pmid |
sentence |
18559524 |
In this report, we describe the preclinical profile of BIBF 1120, a combined VEGFR, FGFR, and PDGFR inhibitor currently entering phase III clinical studies in non–small cell lung carcinoma and other cancers. |
|
Publications: |
1 |
Organism: |
In Vitro |
+ |
nintedanib | down-regulates activity
chemical inhibition
|
FLT4 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-257801 |
|
|
in vitro |
|
pmid |
sentence |
18559524 |
In this report, we describe the preclinical profile of BIBF 1120, a combined VEGFR, FGFR, and PDGFR inhibitor currently entering phase III clinical studies in non–small cell lung carcinoma and other cancers. |
|
Publications: |
1 |
Organism: |
In Vitro |
+ |
nintedanib | down-regulates activity
chemical inhibition
|
FLT1 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-257800 |
|
|
in vitro |
|
pmid |
sentence |
18559524 |
In this report, we describe the preclinical profile of BIBF 1120, a combined VEGFR, FGFR, and PDGFR inhibitor currently entering phase III clinical studies in non–small cell lung carcinoma and other cancers. |
|
Publications: |
1 |
Organism: |
In Vitro |
+ |
nintedanib | down-regulates activity
chemical inhibition
|
FGFR2 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-257806 |
|
|
in vitro |
|
pmid |
sentence |
18559524 |
In this report, we describe the preclinical profile of BIBF 1120, a combined VEGFR, FGFR, and PDGFR inhibitor currently entering phase III clinical studies in non–small cell lung carcinoma and other cancers. |
|
Publications: |
1 |
Organism: |
In Vitro |
+ |
nintedanib | down-regulates activity
chemical inhibition
|
PDGFRA |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-257805 |
|
|
in vitro |
|
pmid |
sentence |
18559524 |
In this report, we describe the preclinical profile of BIBF 1120, a combined VEGFR, FGFR, and PDGFR inhibitor currently entering phase III clinical studies in non–small cell lung carcinoma and other cancers. |
|
Publications: |
1 |
Organism: |
In Vitro |
+ |
nintedanib | down-regulates
chemical inhibition
|
FLT4 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-190302 |
|
|
Homo sapiens |
|
pmid |
sentence |
Other |
|
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
nintedanib | down-regulates activity
chemical inhibition
|
FGFR3 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-257798 |
|
|
in vitro |
|
pmid |
sentence |
18559524 |
In this report, we describe the preclinical profile of BIBF 1120, a combined VEGFR, FGFR, and PDGFR inhibitor currently entering phase III clinical studies in non–small cell lung carcinoma and other cancers. |
|
Publications: |
1 |
Organism: |
In Vitro |
+ |
nintedanib | down-regulates
chemical inhibition
|
FLT1 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-190299 |
|
|
Homo sapiens |
|
pmid |
sentence |
Other |
|
|
Publications: |
1 |
Organism: |
Homo Sapiens |